Thalomid thalidomide: Phase II data; marketed to treat erythema nodosum leprosum in leprosy

National Cancer Institute researchers presented data from 63 androgen independent prostate cancer patients in which 53 and 68 percent of low and high dose Thalomid patients, respectively, had declines...